Clone Algo Technologies Stock (OTC: CATI)

Latest news for Clone Algo Technologies (OTC:CATI) Stock

Clone Algo Technologies Inc is a shell company.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AAME

ARCH BIOPARTNERS INC ORD by Arch Biopartners Inc.

ACHFF

AGEEF

AGRX

AHPI

ASCOT RESOURCES LTD by Ascot Resources Ltd.

AOTVF

ARLP

ARNI

ARTH

BOGN

BRGGF

CADMF

CATI

CLVS

CONC

CPST

CSRH

CTMX

CYIG

DFMTF

DYNT

EBODF

EEVVF

EGTYF

ENCTF

FTXP

GFNL

GGAZF

GOTRF

GTSIF

GXOCF

GXXM

HOTH

IPWG

LENSF

AMERICAN LITHIUM CORP ORD by American Lithium Corp.

LIACF

LVVV

MGPHF

MIRM

MLLOF

MNGGF

MRRMF

MYOV

MYSZ

NOSOF

NUGL

OTIV

PHCEF

PIRE

RMIOF

SAPIF

SNIPF

SOLCF

SXEEQ

TACO

TCHH

UVSE

VEGYF

VEND

VIRA

VQSLF

WKULF

WLDFF

WORK

WTRH

XELA

PNRXF

IBIO

NSHSF

LBHRF

LUCC

ERRCF

RETCD

LINUF

Stocks That Hit 52-Week Lows On Monday

CLONE ALGO TECHS INC by Clone Algo Technologies Inc.

Clone Algo Technologies Inc

Following President Joe Biden&#8217;s decision to <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39885549/biden-withdraws-from-2024-race-what-that-means-for-solana-etf-prospects">withdraw from the 2024 presidential race</a>, a poll conducted by The Wall Street Journal indicates that former President Donald Trump has a slight edge over Vice President Kamala Harris.
What Happened: The poll <a href="https://www.wsj.com/politics/elections/harris-erases-trumps-lead-wsj-poll-finds-e286144d?mod=e2tw">results</a> published on Friday revealed that Trump has the support of 49% of registered voters, while Harris trails slightly behind with 47%. The WSJ poll, conducted from July 23-25, surveyed 1,000 registered voters with a margin of error&nbsp;of ±3.1 percentage points.
The latest poll also showed a significant rise in Harris&#8217;s favorability among registered voters, jumping 11 points to 46%. In comparison, Trump&#8217;s favorability was at 47% and Biden&#8217;s at 39%.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/07/39925959/kim-jong-un-rejects-donald-trumps-friendship-claims-north-korea-says-we-do-not-care-expresses-nuclea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Kim Jong Un Rejects Donald Trump&#8217;s Friendship Claims? North Korea Says &#8216;We Do Not Care,&#8217; Expresses Nuclear Readiness Amid Rising Tension With US</a>
In a ballot test featuring Robert F. Kennedy Jr. alongside other independent and third-party candidates, Harris secured 45% of the vote, while Trump received 44%. Kennedy garnered just 4%, and 5% of voters remained undecided. 
In the last poll, Biden trailed by six points in the multicandidate contest, the report noted.
Why It Matters: The&nbsp;<a href="https://www.benzinga.com/general/politics/24/07/39973800/trump-vs-harris-vice-president-gains-ground-lost-by-joe-biden-in-swing-states">race between Trump and Harris</a>&nbsp;is shaping up to be a close one, with Harris making up ground lost by Biden in head-to-head matchups against Trump. 
President Biden&#8217;s campaign was plagued by a lackluster debate performance and concerns about his age and mental fitness, leading to his withdrawal last week.
Since Biden&#8217;s exit, Harris has garnered several key endorsements from her party, experienced a surge in fundraising, and secured enough delegate commitments to secure the nomination.
Meanwhile, Trump has been&nbsp;<a href="https://www.benzinga.com/news/24/07/39947274/trump-takes-aim-at-kamala-harris-in-first-rally-post-bidens-exit-calls-her-a-radical-left-lunatic-vp">criticizing Harris</a>&nbsp;on immigration and inflation issues, labeling her as a &#8220;radical-left lunatic.&#8221;
There has also been speculation about whether Trump might&nbsp;<a href="https://www.benzinga.com/news/24/07/39979544/can-trump-replace-jd-vance-amid-kamala-harris-picking-pace-experts-warn-that-could-be-extraordinaril">replace his vice presidential candidate</a>, Sen. J.D. Vance, due to the latter&#8217;s underwhelming polling and Harris&#8217;s growing momentum. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39975168/nikki-haley-says-democrats-are-very-smart-to-put-in-a-younger-candidate-against-trump-but-kamala-har?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nikki Haley Says &#8216;Democrats Are Very Smart To Put In A Younger Candidate&#8217; Against Trump But Kamala Harris Is The &#8216;Weakest Candidate&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Politics

Media

Trump Vs. Harris: New Poll Shows Ex-President Leading Democratic Candidate By A Narrow Margin, But Vice President's Favorability Is Faring Better Than Biden

H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) has outperformed the market over the past 5 years by 2.77% on an annualized basis producing an average annual return of 15.37%. Currently, H&amp;R Block has a market capitalization of $7.95 billion. 
Buying $1000 In HRB: If an investor had bought $1000 of HRB stock 5 years ago, it would be worth $2,049.30 today based on a price of $56.95 for HRB at the time of writing.
<h3>H&amp;R Block's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722029438_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today

Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 5.7% on an annualized basis producing an average annual return of 16.62%. Currently, Apollo Global Management has a market capitalization of $69.51 billion. 
Buying $1000 In APO: If an investor had bought $1000 of APO stock 10 years ago, it would be worth $4,546.33 today based on a price of $122.16 for APO at the time of writing.
<h3>Apollo Global Management's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722029433_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Apollo Global Management 10 Years Ago Would Be Worth This Much Today

Citigroup analyst Atif Malik maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Buy and lowers the price target from $185 to $162.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Teradyne, Lowers Price Target to $162

During the last three months, 5 analysts shared their evaluations of Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.0, a high estimate of $7.00, and a low estimate of $7.00. The average price target has stayed the same, reflecting a consistent view from analysts. 
<img src="https://www.benzinga.com/files/images/story/2024/1722027698_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Puma Biotechnology is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Puma Biotechnology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Puma Biotechnology compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Puma Biotechnology's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Puma Biotechnology's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PBYI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Puma Biotechnology analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Puma Biotechnology</h2>
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
<h3>A Deep Dive into Puma Biotechnology's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Challenges: Puma Biotechnology's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -17.07%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Puma Biotechnology's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -11.0%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Puma Biotechnology's ROE stands out, surpassing industry averages. With an impressive ROE of -9.22%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Puma Biotechnology's ROA excels beyond industry benchmarks, reaching -2.17%. This signifies efficient management of assets and strong financial health.
Debt Management: Puma Biotechnology's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.17, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PBYI

Where Puma Biotechnology Stands With Analysts

During the last three months, 10 analysts shared their evaluations of Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Lennox Intl, presenting an average target of $581.9, a high estimate of $675.00, and a low estimate of $517.00. This upward trend is apparent, with the current average reflecting a 7.66% increase from the previous average price target of $540.50.
<img src="https://www.benzinga.com/files/images/story/2024/1722027675_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Lennox Intl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$550.00</td>
<td>$517.00</td>
</tr>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$675.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$572.00</td>
<td>$566.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$600.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$610.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$517.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$575.00</td>
<td>$507.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$570.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Gautam Khanna</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$550.00</td>
<td>$520.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Lennox Intl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lennox Intl compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Lennox Intl's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Lennox Intl's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LII/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lennox Intl analyst ratings.</a>
<h2>Delving into Lennox Intl's Background</h2>
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2023, residential HVAC was 68% of sales and commercial HVAC and Heatcraft refrigeration was 32% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.
<h3>Unraveling the Financial Story of Lennox Intl</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Lennox Intl showcased positive performance, achieving a revenue growth rate of 2.81% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.95%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Lennox Intl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 51.98% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Lennox Intl's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.92% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Lennox Intl's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.72, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Have This To Say About Lennox Intl

Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has outperformed the market over the past 10 years by 12.34% on an annualized basis producing an average annual return of 23.26%. Currently, Taiwan Semiconductor has a market capitalization of $837.03 billion. 
Buying $1000 In TSM: If an investor had bought $1000 of TSM stock 10 years ago, it would be worth $7,815.64 today based on a price of $161.40 for TSM at the time of writing.
<h3>Taiwan Semiconductor's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722027659_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Taiwan Semiconductor 10 Years Ago Would Be Worth This Much Today

Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) has outperformed the market over the past 5 years by 9.75% on an annualized basis producing an average annual return of 22.36%. Currently, Canadian Natural Res has a market capitalization of $73.53 billion. 
Buying $100 In CNQ: If an investor had bought $100 of CNQ stock 5 years ago, it would be worth $279.38 today based on a price of $34.42 for CNQ at the time of writing.
<h3>Canadian Natural Res's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722027654_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Canadian Natural Res Stock In The Last 5 Years

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.5, with a high estimate of $22.50 and a low estimate of $22.50. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1722027642_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Betterware de Mexico SAPI. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Betterware de Mexico SAPI. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Betterware de Mexico SAPI compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Betterware de Mexico SAPI's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Betterware de Mexico SAPI's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BWMX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Betterware de Mexico SAPI analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Betterware de Mexico SAPI: A Closer Look</h2>
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry &amp; cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&amp;PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.
<h3>A Deep Dive into Betterware de Mexico SAPI's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Betterware de Mexico SAPI's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 10.36%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Betterware de Mexico SAPI's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.16% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Betterware de Mexico SAPI's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 19.7%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Betterware de Mexico SAPI's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.68%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 3.6, Betterware de Mexico SAPI adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BWMX

Critical Insights From Betterware de Mexico SAPI Analyst Ratings: What You Need To Know

Canaccord Genuity analyst Dalton Baretto maintains MAG Silver (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#TSX">MAG</a>) with a Buy and raises the price target from C$22 to C$23.

TSX:MAG

Canaccord Genuity Maintains Buy on MAG Silver, Raises Price Target to C$23

Canaccord Genuity analyst Mike Mueller maintains Baytex Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BTE#TSX">BTE</a>) with a Buy and raises the price target from C$6.25 to C$6.5.

TSX:BTE

Canaccord Genuity Maintains Buy on Baytex Energy, Raises Price Target to C$6.5

First Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCAP#NASDAQ">FCAP</a>) reported quarterly earnings of $0.85 per share. This is a 3.66 percent increase over earnings of $0.82 per share from the same period last year.

Earnings

FCAP

First Cap Q2 EPS $0.85 Up From $0.82 YoY

Asset Sales

Johnson Controls International: Purchase Deal Says Robert Bosch Will Pay Co Termination Fee Of $300M If Purchase Agreement Is Terminated

PayPal Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NYSE">PYPL</a>) short percent of float has fallen 4.83% since its last report. The company recently reported that it has 20.55 million shares sold short, which is 1.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PayPal Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722026721_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PayPal Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing PayPal Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PayPal Holdings's peer group average for short interest as a percentage of float is 5.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

PYPL

How Is The Market Feeling About PayPal Holdings?

Owens-Corning's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) short percent of float has risen 10.34% since its last report. The company recently reported that it has 1.49 million shares sold short, which is 2.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Owens-Corning Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722026716_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Owens-Corning has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Owens-Corning's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Owens-Corning's peer group average for short interest as a percentage of float is 4.00%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Owens-Corning's Recent Short Interest

Kohl's's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) short percent of float has risen 4.82% since its last report. The company recently reported that it has 40.73 million shares sold short, which is 51.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Kohl's Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722026711_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kohl's has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Kohl's's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kohl's's peer group average for short interest as a percentage of float is 9.12%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(KSS) - Analyzing Kohl's's Short Interest

<a href="https://www.ft.com/content/d67a6325-d316-4bb8-80e3-1d51429b3393">https://www.ft.com/content/d67a6325-d316-4bb8-80e3-1d51429b3393</a>
Howard Schultz, the former Starbucks chief executive, is opposing a potential settlement between the company and activist investor Elliott Investment Management, in the latest sign of tension at the world's largest coffee chain. The quasi-founder of Starbucks has made his opposition to an Elliott settlement known to some board members, said people familiar with the matter. Schultz had criticised its leadership publicly in recent months despite no longer having a formal role at the company. He remains Starbucks's sixth-largest shareholder, with a holding of about $1.6bn. Elliott, known for being an aggressive investor, has built a sizeable minority stake in the $86bn company and has privately pushed for change in recent weeks, including board representation, in an attempt to revive Starbucks' lacklustre performance. Schultz and Elliott have not been in contact over this matter, one person said. Companies under pressure from activists such as Elliott often seek to negotiate agreements with them rather than face a public fight, but the status of any settlement discussions between Starbucks and Elliott remain unclear. "Howard left the board a year ago and in his limited contact with the board since, his input has always focused on the values and culture of Starbucks as the primary driver of success and performance," a person close to Schultz said. The billionaire former coffee machine salesman led the company three separate times — for about 14 years starting in 1986, then again from 2008 to 2017, and most recently as interim CEO from 2022 to 2023.&nbsp; He was succeeded as CEO last year by Laxman Narasimhan, who joined from UK-based consumer health and hygiene group Reckitt. Schultz remains chair emeritus but left the company's board and has said he does not have access to financial information.
 Schultz, who has said he has no interest in returning as CEO, has remained vocal on the sidelines. This spring he criticised the company's performance on LinkedIn, penning an open letter that said senior leaders and board members needed "to spend more time with those who wear the green apron". He also made an appearance on business podcast Acquired in June, speaking about the history of Starbucks and his recommendations for management. "It hasn't been a great year for Starbucks," he said. "In fairness to Laxman, there's a lot of external issues that have contributed to the pressure, like on every company. But the company has not executed the way that I think it should have." "If the company is doing a drift towards mediocrity, I hold leadership, and the board responsible for that," he said later in the three-hour podcast. Starbucks's share price has fallen about 20 per cent since the start of 2024. The company cut its financial guidance in January and again in April, when it reported a 4 per cent decline in quarterly comparable store sales that was the first such drop since late 2020. It is due to announce results for its fiscal third quarter on Tuesday. Starbucks has made changes to its board over the past year. Three new members, including the CEOs of YouTube and T-Mobile, Neal Mohan and Mike Sievert, joined earlier this year. This spring, Microsoft CEO Satya Nadella left the board. Spokespeople for Schultz, Starbucks and Elliott declined to comment.

Legal

Management

SBUX

'Howard Schultz Opposes Starbucks Settlement With Activist Investor Elliott' - Financial Times

Offerings

ALRN

Aileron Therapeutics Got Into Equity Distribution Agreement, May Offer & Sell Shares Of Our Common Stock From Time To Time Of Up To $50M

WIIM

VTVT

vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 phase 3 trial in type 1 diabetes.

vTv Therapeutics Shares Resume Trade

Clone Algo Technologies

During Monday&#39;s morning session, 81 stocks hit new 52-week lows.

<h3>Noteworthy Highlights:</h3>

<ul>
	<li>Saputo (OTC:<a class="ticker" href="/stock/SAPIF#OTC">SAPIF</a>) was the largest firm on a market cap basis to set a new 52-week low.</li>
	<li>The smallest company by market cap to set a new 52-week low was Porto Energy (OTC:<a class="ticker" href="/stock/PNRXF#OTC">PNRXF</a>).</li>
	<li>Spring Pharmaceutical Gr (OTC:<a class="ticker" href="/stock/CYIG#OTC">CYIG</a>)&#39;s shares had the biggest turnaround, impressively rebounding 900.0% after reaching a new 52-week low.</li>
</ul>

During the first half-hour of trading on Monday, the following stocks set new 52-week lows:

<ul>
	<li>Saputo (OTC:<a class="ticker" href="/stock/SAPIF#OTC">SAPIF</a>) stock hit $28.10 on Monday morning, setting a new 52-week low. The stock traded down 2.47% over the course of the day.</li>
	<li>Slack Technologies (NYSE:<a class="ticker" href="/stock/WORK#NYSE">WORK</a>) shares were down 1.36% over the session, having began the day with a 52-week low of $20.21.</li>
	<li>PG&amp;E (NYSE:<a class="ticker" href="/stock/PCG#NYSE">PCG</a>) stock set a new 52-week low of $3.81 on Monday morning, with shares later moving down 20.9%.</li>
	<li>Six Flags Entertainment (NYSE:<a class="ticker" href="/stock/SIX#NYSE">SIX</a>) shares were up 0.02% over the session, having began the day with a 52-week low of $42.75.</li>
	<li>Alliance Resource (NASDAQ:<a class="ticker" href="/stock/ARLP#NASDAQ">ARLP</a>) shares fell to $13.31 on Monday morning, setting a new 52-week low. Shares then moved down 6.67%.</li>
	<li>PharmaCielo (OTC:<a class="ticker" href="/stock/PHCEF#OTC">PHCEF</a>) stock set a new 52-week low of $2.42 on Monday morning, with shares later moving down 5.12%.</li>
	<li>GAMCO Investors (NYSE:<a class="ticker" href="/stock/GBL#NYSE">GBL</a>) shares were down 0.24% over the session, having began the day with a 52-week low of $15.91.</li>
	<li>Myovant Sciences (NYSE:<a class="ticker" href="/stock/MYOV#NYSE">MYOV</a>) shares set a new yearly low of $4.45 this morning. The stock was down 0.67% on the session.</li>
	<li>Clone Algo Technologies (OTC:<a class="ticker" href="/stock/CATI#OTC">CATI</a>) shares fell to $2.55 on Monday morning, setting a new 52-week low. Shares then moved 0.0% (flat).</li>
	<li>Del Taco Restaurants (NASDAQ:<a class="ticker" href="/stock/TACO#NASDAQ">TACO</a>) shares reached a new 52-week low of $7.83 on Monday morning, later moving down 1.77% over the rest of the day.</li>
	<li>PolyMet Mining (AMEX:<a class="ticker" href="/stock/PLM#AMEX">PLM</a>) shares moved down 0.99% on Monday&#39;s session after setting a new 52-week low of $0.30 to begin trading.</li>
	<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="/stock/CTMX#NASDAQ">CTMX</a>) shares hit a yearly low of $6.27 today morning. The stock was up 0.94% on the session.</li>
	<li>Clovis Oncology (NASDAQ:<a class="ticker" href="/stock/CLVS#NASDAQ">CLVS</a>) shares reached a new 52-week low of $2.99 on Monday morning, later moving down 0.33% over the rest of the day.</li>
	<li>Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="/stock/MIRM#NASDAQ">MIRM</a>) shares set a new 52-week low of $7.33 today morning. The stock traded down 2.66% over the session.</li>
	<li>Exela Technologies (NASDAQ:<a class="ticker" href="/stock/XELA#NASDAQ">XELA</a>) shares fell to $0.79 on Monday morning, setting a new 52-week low. Shares then moved down 0.26%.</li>
	<li>Ascot Resources (OTC:<a class="ticker" href="/stock/AOTVF#OTC">AOTVF</a>) stock hit $0.35 on Monday morning, setting a new 52-week low. The stock traded down 5.14% over the course of the day.</li>
	<li>Waitr Hldgs (NASDAQ:<a class="ticker" href="/stock/WTRH#NASDAQ">WTRH</a>) shares hit a yearly low of $0.50 today morning. The stock was down 10.66% on the session.</li>
	<li>Noront Resources (OTC:<a class="ticker" href="/stock/NOSOF#OTC">NOSOF</a>) stock fell to a new 52-week low on Monday morning at $0.15, and later moved down 13.65% over the session.</li>
	<li>Halo Labs (OTC:<a class="ticker" href="/stock/AGEEF#OTC">AGEEF</a>) shares set a new yearly low of $0.17 this morning. The stock was down 10.4% on the session.</li>
	<li>Chemesis International (OTC:<a class="ticker" href="/stock/CADMF#OTC">CADMF</a>) shares reached a new 52-week low of $0.30 on Monday morning, later moving down 1.55% over the rest of the day.</li>
	<li>Eve (OTC:<a class="ticker" href="/stock/EEVVF#OTC">EEVVF</a>) shares moved up 8.14% on Monday&#39;s session after setting a new 52-week low of $0.10 to begin trading.</li>
	<li>Agile Therapeutics (NASDAQ:<a class="ticker" href="/stock/AGRX#NASDAQ">AGRX</a>) stock hit $0.52 on Monday morning, setting a new 52-week low. The stock traded down 56.49% over the course of the day.</li>
	<li>Arch Biopartners (OTC:<a class="ticker" href="/stock/ACHFF#OTC">ACHFF</a>) stock fell to a new 52-week low of $0.71 on Monday morning. Shares of the company traded 0.0% (flat) on the day.</li>
	<li>Pintec Technology Hldgs (NASDAQ:<a class="ticker" href="/stock/PT#NASDAQ">PT</a>) shares hit a yearly low of $0.96 today morning. The stock was down 8.26% on the session.</li>
	<li>Atlantic American (NASDAQ:<a class="ticker" href="/stock/AAME#NASDAQ">AAME</a>) stock fell to a new 52-week low on Monday morning at $2.07, and later moved down 0.91% over the session.</li>
	<li>SOL Global Investments (OTC:<a class="ticker" href="/stock/SOLCF#OTC">SOLCF</a>) shares began trading with a new 52-week low of $0.45 on Monday. The stock was down 7.77% for the day.</li>
	<li>Hoth Therapeutics (NASDAQ:<a class="ticker" href="/stock/HOTH#NASDAQ">HOTH</a>) stock fell to a new 52-week low of $3.75 on Monday morning. Shares of the company traded down 6.25% on the day.</li>
	<li>Arch Therapeutics (OTC:<a class="ticker" href="/stock/ARTH#OTC">ARTH</a>) shares began trading with a new 52-week low of $0.12 on Monday. The stock was up 12.84% for the day.</li>
	<li>Viratech (OTC:<a class="ticker" href="/stock/VIRA#OTC">VIRA</a>) shares were down 16.92% over the session, having began the day with a 52-week low of $0.01.</li>
	<li>Capstone Turbine (NASDAQ:<a class="ticker" href="/stock/CPST#NASDAQ">CPST</a>) shares hit a yearly low of $2.33 today morning. The stock was down 5.83% on the session.</li>
	<li>Mason Graphite (OTC:<a class="ticker" href="/stock/MGPHF#OTC">MGPHF</a>) stock moved down 2.07% over Monday&#39;s trading session after setting a new 52-week low of $0.15 to open trading.</li>
	<li>Weekend Unlimited (OTC:<a class="ticker" href="/stock/WKULF#OTC">WKULF</a>) shares moved down 10.0% on Monday&#39;s session after setting a new 52-week low of $0.03 to begin trading.</li>
	<li>Pierre (OTC:<a class="ticker" href="/stock/PIRE#OTC">PIRE</a>) shares hit a yearly low of $0.95 today morning. The stock was down 5.94% on the session.</li>
	<li>Wildflower Brands (OTC:<a class="ticker" href="/stock/WLDFF#OTC">WLDFF</a>) stock moved up 0.98% over Monday&#39;s trading session after setting a new 52-week low of $0.20 to open trading.</li>
	<li>Generation Next Franchise (OTC:<a class="ticker" href="/stock/VEND#OTC">VEND</a>) shares set a new yearly low of $0.20 this morning. The stock was down 26.89% on the session.</li>
	<li>Eguana Technologies (OTC:<a class="ticker" href="/stock/EGTYF#OTC">EGTYF</a>) shares moved down 11.47% on Monday&#39;s session after setting a new 52-week low of $0.06 to begin trading.</li>
	<li>SandRidge Mississippian (NYSE:<a class="ticker" href="/stock/SDR#NYSE">SDR</a>) stock hit $0.29 on Monday morning, setting a new 52-week low. The stock traded down 21.47% over the course of the day.</li>
	<li>Granite Oil (OTC:<a class="ticker" href="/stock/GXOCF#OTC">GXOCF</a>) shares were down 0.14% over the session, having began the day with a 52-week low of $0.32.</li>
	<li>VIQ Solutions (OTC:<a class="ticker" href="/stock/VQSLF#OTC">VQSLF</a>) shares fell to $0.07 on Monday morning, setting a new 52-week low. Shares then moved down 15.29%.</li>
	<li>Bragg Gaming Group (OTC:<a class="ticker" href="/stock/BRGGF#OTC">BRGGF</a>) shares reached a new 52-week low of $0.14 on Monday morning, later moving down 4.62% over the rest of the day.</li>
	<li>Genesis Financial (OTC:<a class="ticker" href="/stock/GFNL#OTC">GFNL</a>) shares were down 25.0% over the session, having began the day with a 52-week low of $0.30.</li>
	<li>NUGL (OTC:<a class="ticker" href="/stock/NUGL#OTC">NUGL</a>) shares were down 5.38% over the session, having began the day with a 52-week low of $0.24.</li>
	<li>SandRidge Mississippian (NYSE:<a class="ticker" href="/stock/SDT#NYSE">SDT</a>) stock hit a new 52-week low of $0.34 to begin trading. The stock was down 11.75% on the session.</li>
	<li>On Track Innovations (NASDAQ:<a class="ticker" href="/stock/OTIV#NASDAQ">OTIV</a>) stock set a new 52-week low of $0.24 on Monday morning, with shares later moving down 19.98%.</li>
	<li>My Size (NASDAQ:<a class="ticker" href="/stock/MYSZ#NASDAQ">MYSZ</a>) shares reached a new 52-week low of $0.40 on Monday morning, later moving up 0.09% over the rest of the day.</li>
	<li>iBio (AMEX:<a class="ticker" href="/stock/IBIO#AMEX">IBIO</a>) stock fell to a new 52-week low of $0.20 on Monday morning. Shares of the company traded down 8.01% on the day.</li>
	<li>Dynatronics (NASDAQ:<a class="ticker" href="/stock/DYNT#NASDAQ">DYNT</a>) stock moved up 1.69% over Monday&#39;s trading session after setting a new 52-week low of $0.85 to open trading.</li>
	<li>American Lithium (OTC:<a class="ticker" href="/stock/LIACF#OTC">LIACF</a>) shares set a new 52-week low of $0.09 today morning. The stock traded down 2.0% over the session.</li>
	<li>Nanosphere Health (OTC:<a class="ticker" href="/stock/NSHSF#OTC">NSHSF</a>) stock fell to a new 52-week low on Monday morning at $0.03, and later moved down 26.86% over the session.</li>
	<li>Goliath Resources (OTC:<a class="ticker" href="/stock/GOTRF#OTC">GOTRF</a>) stock hit a yearly low of $0.03 this morning. The stock was down 49.02% for the day.</li>
	<li>Romios Gold Resources (OTC:<a class="ticker" href="/stock/RMIOF#OTC">RMIOF</a>) shares hit a yearly low of $0.02 today morning. The stock was 0.0% (flat) on the session.</li>
	<li>Snipp Interactive (OTC:<a class="ticker" href="/stock/SNIPF#OTC">SNIPF</a>) stock set a new 52-week low of $0.01 on Monday morning, with shares later moving down 2.05%.</li>
	<li>New Energy Exchange (OTC:<a class="ticker" href="/stock/EBODF#OTC">EBODF</a>) shares hit a yearly low of $0.20 today morning. The stock was down 54.55% on the session.</li>
	<li>Universal Energy (OTC:<a class="ticker" href="/stock/UVSE#OTC">UVSE</a>) shares were 0.0% (flat) over the session, having began the day with a 52-week low of $0.000001.</li>
	<li>Mongolia Growth Group (OTC:<a class="ticker" href="/stock/MNGGF#OTC">MNGGF</a>) shares set a new yearly low of $0.14 this morning. The stock was down 11.25% on the session.</li>
	<li>Goldgroup Mining (OTC:<a class="ticker" href="/stock/GGAZF#OTC">GGAZF</a>) stock fell to a new 52-week low of $0.01 on Monday morning. Shares of the company traded down 50.0% on the day.</li>
	<li>Miramont Resources (OTC:<a class="ticker" href="/stock/MRRMF#OTC">MRRMF</a>) shares set a new 52-week low of $0.06 today morning. The stock traded down 10.38% over the session.</li>
	<li>Greenstar Biosciences (OTC:<a class="ticker" href="/stock/GTSIF#OTC">GTSIF</a>) shares hit a yearly low of $0.06 today morning. The stock was down 30.92% on the session.</li>
	<li>Spring Pharmaceutical Gr (OTC:<a class="ticker" href="/stock/CYIG#OTC">CYIG</a>) shares fell to $0.08 on Monday morning, setting a new 52-week low. Shares then moved down 4.76%.</li>
	<li>Bogen Communications Intl (OTC:<a class="ticker" href="/stock/BOGN#OTC">BOGN</a>) stock hit $0.03 on Monday morning, setting a new 52-week low. The stock traded down 19.35% over the course of the day.</li>
	<li>Allied Healthcare Prods (NASDAQ:<a class="ticker" href="/stock/AHPI#NASDAQ">AHPI</a>) shares reached a new 52-week low of $1.20 on Monday morning, later moving down 7.45% over the rest of the day.</li>
	<li>Encanto Potash (OTC:<a class="ticker" href="/stock/ENCTF#OTC">ENCTF</a>) shares began trading with a new 52-week low of $0.06 on Monday. The stock was down 14.73% for the day.</li>
	<li>Medallion Resources (OTC:<a class="ticker" href="/stock/MLLOF#OTC">MLLOF</a>) stock fell to a new 52-week low of $0.05 on Monday morning. Shares of the company traded down 8.97% on the day.</li>
	<li>Defense Metals (OTC:<a class="ticker" href="/stock/DFMTF#OTC">DFMTF</a>) stock set a new 52-week low of $0.06 on Monday morning, with shares later moving down 20.44%.</li>
	<li>NxGold (OTC:<a class="ticker" href="/stock/LBHRF#OTC">LBHRF</a>) stock hit a yearly low of $0.03 this morning. The stock was down 28.57% for the day.</li>
	<li>Virginia Energy Resources (OTC:<a class="ticker" href="/stock/VEGYF#OTC">VEGYF</a>) stock hit a yearly low of $0.03 this morning. The stock was 0.0% (flat) for the day.</li>
	<li>Luca (OTC:<a class="ticker" href="/stock/LUCC#OTC">LUCC</a>) shares set a new 52-week low of $0.01 today morning. The stock traded down 50.5% over the session.</li>
	<li>Livewire Ergogenics (OTC:<a class="ticker" href="/stock/LVVV#OTC">LVVV</a>) stock fell to a new 52-week low on Monday morning at $0.01, and later moved down 13.04% over the session.</li>
	<li>WestKam Gold (OTC:<a class="ticker" href="/stock/ERRCF#OTC">ERRCF</a>) shares moved down 72.92% on Monday&#39;s session after setting a new 52-week low of $0.00065 to begin trading.</li>
	<li>Conectisys (OTC:<a class="ticker" href="/stock/CONC#OTC">CONC</a>) shares were up 25.0% over the session, having began the day with a 52-week low of $0.0012.</li>
	<li>Southcross Energy (OTC:<a class="ticker" href="/stock/SXEEQ#OTC">SXEEQ</a>) stock moved down 16.67% over Monday&#39;s trading session after setting a new 52-week low of $0.01 to open trading.</li>
	<li>GEX Management (OTC:<a class="ticker" href="/stock/GXXM#OTC">GXXM</a>) shares were down 99.0% over the session, having began the day with a 52-week low of $0.000001.</li>
	<li>12 Retech (OTC:<a class="ticker" href="/stock/RETCD#OTC">RETCD</a>) shares hit a yearly low of $0.0031 today morning. The stock was up 38.79% on the session.</li>
	<li>Foothills Exploration (OTC:<a class="ticker" href="/stock/FTXP#OTC">FTXP</a>) shares set a new yearly low of $0.0032 this morning. The stock was down 20.93% on the session.</li>
	<li>Presbia (OTC:<a class="ticker" href="/stock/LENSF#OTC">LENSF</a>) shares hit a yearly low of $0.01 today morning. The stock was 0.0% (flat) on the session.</li>
	<li>International Power Group (OTC:<a class="ticker" href="/stock/IPWG#OTC">IPWG</a>) shares reached a new 52-week low of $0.000001 on Monday morning, later moving down 99.0% over the rest of the day.</li>
	<li>Consorteum Holdings (OTC:<a class="ticker" href="/stock/CSRH#OTC">CSRH</a>) shares moved down 33.33% on Monday&#39;s session after setting a new 52-week low of $0.0002 to begin trading.</li>
	<li>Arno Therapeutics (OTC:<a class="ticker" href="/stock/ARNI#OTC">ARNI</a>) stock hit $0.001 on Monday morning, setting a new 52-week low. The stock traded 0.0% (flat) over the course of the day.</li>
	<li>LiNiu Technology Group (OTC:<a class="ticker" href="/stock/LINUF#OTC">LINUF</a>) shares were down 47.96% over the session, having began the day with a 52-week low of $0.0014.</li>
	<li>Trustcash Holdings (OTC:<a class="ticker" href="/stock/TCHH#OTC">TCHH</a>) shares began trading with a new 52-week low of $0.000001 on Monday. The stock was 0.0% (flat) for the day.</li>
	<li>Porto Energy (OTC:<a class="ticker" href="/stock/PNRXF#OTC">PNRXF</a>) stock hit $0.00001 on Monday morning, setting a new 52-week low. The stock traded up 900.0% over the course of the day.</li>
</ul>

 
Benzinga will continue to update investors on further movements in these equities. Stay tuned.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Clone Algo Technologies

News

Latest news for Clone Algo Technologies (OTC:CATI) Stock

Monday, October 28, 2019